Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man
Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man
复制标题
DOI：
10.1080/01652176.2013.873963
复制
发表时间：
2013-12-01
影响因子：
6.4
通讯作者：
Meyer, Evelyne
中科院分区：
文献类型：
--
作者：
de Bakker, Evelien;Van Ryssen, Bernadette;Meyer, Evelyne
对间充质干细胞(MSCs)用于犬的再生和修复治疗的兴趣正在显现，因为目前针对几种情况的治疗方案往往不能产生预期的临床结果或患者恢复正常功能。此外，由于狗被认为是比啮齿动物更好的人类模型，狗的骨髓间充质干细胞已经在一些关于人类新疗法的有效性和安全性测试的实验和临床前研究中进行了评估。尽管这些间充质干细胞可以从几个来源获得，但临床应用更倾向于骨髓和脂肪组织，因为它们相对容易回收干细胞，而且供体部位的发病率最低。在任何类型的干细胞可以应用于临床之前，通过一组特定的功能或表型标记对其进行明确的表征是至关重要的。然而，到目前为止，犬MSCs还没有统一的鉴定标准。此外，虽然在少数研究中已经证实了犬MSCs的多向分化潜能，但目前犬医学领域仍缺乏对MSCs向腱细胞分化潜能的研究。相比之下，后一个主题已经在人类和马医学中进行了探索，证明了需要一个特定的利基环境，即对MSC分化具有积极影响的因素。由于关于犬MSC的这些因素中的大多数仍然未知，迫切需要关键的基础知识来激励和正确地翻译这些干细胞在狗和人身上的潜在治疗应用。
Interest in mesenchymal stem cells (MSCs) both for regenerative and reparative therapies in dogs is emerging, as the current treatment options for several conditions often do not result either in the desired clinical outcome or in the patients' return to normal function. In addition, canine MSCs have been evaluated in some experimental and preclinical studies on efficacy and safety testing of novel treatments for humans, since the dog is considered to be a superior model for humans than rodents. Although these MSCs can be derived from several sources, clinical use has favoured bone marrow and adipose tissue because of their relative ease of stem cell recovery and the minimal donor-site morbidity. Before any type of stem cell can be applied clinically, its unequivocal characterization by a set of specific functional or phenotypic markers is crucial. However, no uniform characterization criteria are available for canine MSCs so far. Moreover, although multi-lineage potential of canine MSCs has been demonstrated in a limited number of studies, research on the differentiation potential of MSCs towards tenocytes is still lacking in canine medicine. In contrast, this latter subject has been explored already in human as well as in equine medicine, demonstrating the need for a specific niche', i.e. factors with a positive influence on the MSC differentiation. Since most of these factors are still unknown regarding canine MSC, critical basic knowledge is urgently required to motivate and correctly translate the potential therapeutic applications of these stem cells in both dog and man.